Use of highly active antiretroviral therapy in patients infected with HIV can lead to lipodystrophy, a condition characterized by changes in body-fat distribution. In addition, infected individuals often exhibit relative growth hormone (GH) deficiency. Treatment with supraphysiological levels of GH improves body composition in these patients, but is associated with adverse effects. In this Practice Point commentary, we discuss an 18-month, randomized, double-blind, placebo-controlled study of low-dose GH therapy in 56 HIV-positive adults with lipodystrophy and relative GH deficiency. Lo et al. found that administration of low-dose GH (mean 0.33 mg daily) led to improvements in body composition (e.g. visceral adipose-tissue area), diastolic blood pressure and triglyceride levels. Furthermore, this treatment regimen was not associated with an increased incidence of adverse events compared with placebo. Here, we discuss the implications of the findings of Lo et al., and describe additional strategies that might be used to treat lipodystrophy in HIV-positive individuals.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Chen D et al. (2002) Clinical review 153: lipodystrophy in human immunodeficiency virus-infected patients. J Clin Endocrinol Metab 87: 4845–4856
Friis-Møeller N et al. (2003) Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 349: 1993–2003
Koutkia P et al. (2005) Growth hormone (GH) responses to GH-releasing hormone-arginine testing in human immunodeficiency virus lipodystrophy. J Clin Endocrinol Metab 90: 32–38
Lo JC et al. (2001) The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 86: 3480–3487
Lo J et al. (2008) Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial. JAMA 300: 509–519
Falutz J et al. (2007) Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 357: 2359–2370
Nass R et al. (2008) Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 149: 601–611
Michael O Thorner holds a patent for treatment of sarcopenia with growth hormone secretagogues (US Patent 7442706: methods for treating sarcopenia with growth hormone secretogogue).
Ralf Nass declared no competing interests.
About this article
Cite this article
Nass, R., Thorner, M. Does low-dose growth hormone therapy improve the body composition of patients infected with HIV?. Nat Rev Endocrinol 5, 142–143 (2009). https://doi.org/10.1038/ncpendmet1064